Same asset, new use: management describes redeploying something the company already owns into a materially higher-value
The model's full reasoning — Q4 2022 call → NOThe question asks whether management describes the company currently putting something it already owns or already does to a different and materially more valuable use than the use it was originally built, bought, or intended for — and that this change of use is already happening now, with real activity behind it. Looking at the transcript, the key candidate is the sale of olpasiran royalty rights to Royalty Pharma. Let me examine this carefully. Chris Anzalone says: "we recently decided to sell the potential royalties we would receive from Amgen on future olpasiran sales to Royalty Pharma. We received $250 million in cash upfront and up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones." Is this a "change of purpose for something already in hand"? The company had a royalty interest in olpasiran (a drug it developed and out-licensed to Amgen). It sold that royalty interest to Royalty Pharma. This is selling an asset, not repurposing it. The question asks about "putting something it already owns or already does to a different and materially more valuable use" — the essence is "value being created not by adding new assets but by discovering that assets the company already paid for are worth more doing something else, and acting on that discovery now." Selling a royalty stream is not really "putting an asset to a different use" — it's monetizing/selling the asset. The question's NO criteria says: "NO if the shift is chiefly selling, closing, or writing down the asset rather than operating it differently." So the royalty sale is chiefly selling an asset, not operating it differently. That would be a NO. What about the "20 in '25" program? That's about expanding the pipeline — adding new drug candidates. That's growth/expansion, not repurposing existing assets. What about the pulmonary programs (ARO-RAGE, ARO-MUC5AC)? These are new candidates in development — not yet approved, not yet in market. The question requires the thing being redirected to "already exist and belong to the company — it is not being newly acquired, invented, or awaited." These are in clinical trials, so they exist, but are they being "pointed at a new purpose"? They were always intended for pulmonary diseases. No change of purpose.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
APPS · Q1 2024 → YESThe question is whether management describes currently putting something they already own or do to a different and materially more valuable use, and that this is already happening now. YES Bill Stone describes using the company’s existing on-device technology and installed base of hundreds of millions of devices (already owned and paid for) for a new purpose: alternative app distribution via DT Hub and SingleTap monetization. He states they have launched DT Hub with four U.S. operators and are generating revenue today with incremental higher RPDs from devices engaging with the Hub product, and they are leveraging existing hub capabilities to enable direct distribution outside Apple/Google stores. This is presented as already happening now, with the new use delivering better economics through higher RPD accretion and expanded revenue streams.
PRPH · Q1 2023 → YESThe question is whether management describes currently putting something they already own or do to a different and materially more valuable use, and that this change is already happening now. YES The transcript shows management describing a clear redirection of assets already owned: the manufacturing facility (originally kept solely for Cold-EEZE infrastructure after the brand sale) is now being run for third-party lozenge manufacturing, with revenues growing nearly 100% year-over-year and $25 million targeted for 2024 — a use they explicitly call “the least interesting business” yet one with “enormous value” and an estimated $70 million next-year market value.
GGR · Q1 2023 → YESThe question is about whether Gogoro is currently putting something it already owns or does to a different and materially more valuable use. YES The transcript shows Gogoro is already redirecting its existing battery-swapping network and smart batteries (originally built for vehicle swaps) into a new Virtual Power Plant use case via the Enel X partnership.